Supernus Pharmaceuticals (SUPN) Gross Margin (2013 - 2025)
Supernus Pharmaceuticals (SUPN) reported Gross Margin of 89.13% for Q4 2025, up 411.0% year-over-year from 17.44% in Q4 2024, and down 1.11% quarter-over-quarter from 90.13% in Q3 2025.
Supernus Pharmaceuticals (SUPN) Gross Margin (2013 - 2025) Analysis & Trends
Supernus Pharmaceuticals (SUPN) has 13 years of Gross Margin data on file, last reported at 89.13% in Q4 2025.
- Gross Margin for Q4 2025 came in at 89.13%, up 411.0% year-over-year; the trailing twelve-month figure through Dec 2025 was 89.63% (up 140.0% YoY), and the FY2025 annual result was 89.63%, up 140.0% from the prior year.
- Gross Margin fell to 89.13% in Q4 2025 per SUPN's latest filing, from 90.13% in the prior quarter.
- Over five years, Gross Margin peaked at 90.13% in Q3 2025 and troughed at 82.29% in Q2 2021.
- A 5-year average of 87.6% and a median of 88.15% in 2023 frame the typical range for Gross Margin.
- The sharpest annual moves came in 2021 and 2022: Gross Margin tumbled 1109 bps in 2021, then surged 568 bps in 2022.
- A 5-year view of Gross Margin shows it stood at 89.32% in 2021, then slipped by 3 bps to 86.28% in 2022, then rose by 2 bps to 88.06% in 2023, then dropped by 3 bps to 85.01% in 2024, then gained by 5 bps to 89.13% in 2025.
- Business Quant data shows SUPN's Gross Margin at 89.13% in Q4 2025, 90.13% in Q3 2025, and 89.83% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 49.52% |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 71.66% |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 82.93% |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | 49.50% |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 98.31% |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 57.26% |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | -293.83% |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 61.20% |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | 65.25% |
| 10 | Supernus Pharmaceuticals | 2.57 Bn | 2.19 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 89.13% |
| Sep 30, 2025 | 90.13% |
| Jun 30, 2025 | 89.83% |
| Mar 31, 2025 | 89.48% |
| Dec 31, 2024 | 85.01% |
| Sep 30, 2024 | 89.99% |
| Jun 30, 2024 | 89.36% |
| Mar 31, 2024 | 88.65% |
| Dec 31, 2023 | 88.06% |
| Sep 30, 2023 | 87.26% |
| Jun 30, 2023 | 84.44% |
| Mar 31, 2023 | 84.74% |
| Dec 31, 2022 | 86.28% |
| Sep 30, 2022 | 85.41% |
| Jun 30, 2022 | 87.97% |
| Mar 31, 2022 | 88.24% |
| Dec 31, 2021 | 89.32% |
| Sep 30, 2021 | 87.82% |
| Jun 30, 2021 | 82.29% |
| Mar 31, 2021 | 88.58% |